Neuron23 Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 leverages recent advances in human genetics, combined with their state-of-the-art artificial intelligence (AI)-enabled drug discovery and biomarker platforms, to advance therapeutics for devastating diseases. The Company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Founded in 2018, Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, CA, and Munich, Germany.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/16/20 | $113,500,000 | Series A and B |
Acorn Bioventures Cowen Healthcare Investments HBM Partners Kleiner Perkins Caufield and Byers Perceptive Advisors Redmile Group  Surveyor Capital Westlake Village BioPartners | undisclosed |
| 03/30/22 | $100,000,000 | Series C |
Acorn Bioventures Cowen Healthcare Investments HBM BioCapital Kleiner Perkins Caufield and Byers Perceptive Advisors Redmile Group SoftBank Vision Fund 2 Surveyor Capital Westlake Village BioPartners | undisclosed |
